Clinical trial NCT04460729: A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
Official title: A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, Non Small-Cell Lung Cancer That Has Metastasized to the Brain
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Non-small Cell Lung Carcinoma (NSCLC)
Keywords: Non-small cell lung carcinoma
Non-small cell lung cancer
NSCLC
Treatment of lung cancer after first metastasi
Lung cancer
Lung adenocarcinoma
Squamous cell lung carcinoma
Large-cell lung carcinoma
Large-cell lung cancer
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2020-07-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Approximately 60 participants will be enrolled globally and allocated to one of two cohorts based on whether their metastatic brain disease is symptomatic or asymptomatic and with or without prior brain therapy or if they have been diagnosed with leptomeningeal disease
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to establish the intracranial efficacy of single agent capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of systemic therapies for advanced stage Non Small-Cell Lung Cancer (NSCLC) with MET exon 14 mutation that has metastasized to the brain.

Cohort 1 (asymptomatic brain metastases (BM) without prior brain therapy) has been selected to identify patients who are most likely to benefit from capmatinib therapy in this setting and to establish a clinically relevant response outcome.

Cohort 2 is a heterogeneous group of patients (symptomatic with and without prior brain therapy, asymptomatic with prior brain therapy, or with leptomeningeal disease.), and the outcomes will be descriptive only

Detailed description: This is a prospectively designed, multicenter, open-label, two-cohort, phase II study to evaluate the intracranial efficacy of single agent capmatinib in participants with MET exon 14 mutated NSCLC and BM. Participants can be treatment naïve or pretreated with one or two prior lines of systemic therapies for advanced stage (stage IIIb - IV) NSCLC.

Approximately 60 participants will be enrolled globally and allocated to one of two cohorts:

Cohort 1 will enroll approximately 40 participants who are asymptomatic and without prior brain therapy.

Cohort 2 will enroll approximately 20 participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease.

All participants will be pre-screened for MET mutation and presence of BM will be documented at baseline by a radiologist/neuroradiologist.

Intracranial disease will be assessed and response to treatment will be evaluated using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria every 8 weeks. Extracranial and whole body disease will be assessed and response to treatment will be evaluated using RECIST 1.1 every 8 weeks.

Participants will receive capmatinib 400 mg b.i.d. until they experience any of the following: documented disease progression by RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and confirmed by BIRC), withdrawal of consent, pregnancy, lost to follow-up, or death.

For all participants, treatment with capmatinib may be continued beyond initial progression disease (PD) as per RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and confirmed by BIRC) if, in the judgment of the investigator, there is evidence of clinical benefit, and the participant wishes to continue on the study treatment.

After treatment discontinuation, all participants will be followed for safety evaluations during the safety follow-up period, and the participant's status will be collected every 12 weeks as part of the survival follow-up.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed stage IV (according to Version 8 of the American Joint Committee on Cancer (AJCC)) NSCLC that is EGFR wt, ALK rearrangement negative as assessed by a validated test as part of the participant's standard of care and has MET∆ex14 mutation per Novartis-designated central laboratory or (US only) locally with FoundationOne Companion Diagnostic (F1CDx) .
* Treatment naïve or up to two prior lines of systemic therapy for stage IIIb-IV NSCLC
* Measurable intracranial lesions:

  1. Cohort 1 and Cohort 2 (without leptomeningeal carcinoma): At least 1 measurable intracranial lesion per RANO-BM criteria, documented by a radiologist/neuroradiologist (treated or untreated).
  2. Cohort 2 (with leptomeningeal carcinoma): participants with leptomeningeal carcinoma may not have measurable lesions. In this circumstance, the participant's disease will be considered to have non-target lesions only at baseline and their response based on descriptive clinical criteria by physician assessment.
* Capable of undergoing magnetic resonance imaging (MRI)
* ECOG performance status of 0 or 1

Exclusion Criteria:

* Only for Cohort 1: any neurological symptoms related to brain metastases
* For participants in Cohort 2 with prior brain therapy: Treatment with stereotactic radiosurgery within 14 days prior to the start of study treatment or treatment with WBRT within 14 days prior to the start of study treatment
* Prior treatment with any MET targeting therapy or HGF inhibitor
* Participants with other known druggable molecular alterations (such as ROS1 translocation or BRAF mutation) who might be candidates to alternative targeted therapies as applicable per local regulations and treatment guidelines
* Presence or history of ILD or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
* Clinically significant, uncontrolled heart diseases including History of familial long QT syndrome, sudden death or congenital long QT syndrome

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Overall Intracranial Response Rate (OIRR) in Cohort 1 by Blinded Independent Review Committee (BIRC) review
timeFrame: Up to 36 months
Secondary outcomes:
measure: Overall Intracranial Response Rate (OIRR) in Cohort 1 by investigator review
timeFrame: Up to 36 months
measure: Intracranial Disease Control Rate (IDCR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Time to intracranial tumor Response (TTIR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Duration of Intracranial Response (DOIR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Overall Intracranial Response Rate (OIRR) in Cohort 2 by investigator and BIRC review
timeFrame: Up to 36 months
measure: Overall Extracranial Response Rate (OERR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Extracranial Disease Control Rate (EDCR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Time to Extracranial Response (TTER) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Duration of Extracranial Response (DOER) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Overall Response Rate (ORR) per RECIST 1.1 by investigator and BIRC review
timeFrame: Up to 36 months
measure: Time to response (TTR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Duration of response (DOR) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Progression free survival (PFS) by investigator and BIRC review
timeFrame: Up to 36 months
measure: Overall survival (OS)
timeFrame: Up to 36 months
measure: Percentage of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to 36 months
measure: Number of participants with dose interruptions
timeFrame: Up to 29 months
measure: Number of participants with dose reductions
timeFrame: Up to 29 months
measure: Dose intensity
timeFrame: Up to 29 months
measure: Time to deterioration in Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) scores in Cohort 1
timeFrame: Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
measure: Change from baseline in score as per FACT-Brain Symptom Index (FBrSI) in Cohort 2
timeFrame: Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
measure: Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30
timeFrame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
measure: Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)
timeFrame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
measure: Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire
timeFrame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: